MannKind Corporation ( MNKD) has disclosed a new risk, in the Capital Markets category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung ...

MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed ...

MannKind Corporation (NASDAQ:MNKD) is one of the best strong buy penny stocks to buy now. In a report released on July 29, ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind Corp (NASDAQ:MNKD) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue ...

MannKind Corporation (NASDAQ: MNKD) is one of the best biotech penny stocks to buy right now. Analyst Yun Zhong from Wedbush ...

MannKind Corporation beats analysts on earnings and revenue in Q2 2023, with a year-over-year increase of 157.3% in revenue. Strong demand for Afrezza and Tyvaso DPI contributes to revenue growth.

MannKind Corporation shares are trending on social media Monday. CNBC's Jim Cramer mentioned the stock on the "Mad Money Lightning Round" Friday. The stock has been "hanging out ...

Shares of MannKind Corp. MNKD fell 1.5% premarket on Monday after the biopharma company said a fire at a German manufacturing facility may delay the planned initiation later this year of a phase 2 ...